Literature DB >> 18593903

Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis.

Jharna Datta1, Huban Kutay, Mohd W Nasser, Gerard J Nuovo, Bo Wang, Sarmila Majumder, Chang-Gong Liu, Stefano Volinia, Carlo M Croce, Thomas D Schmittgen, Kalpana Ghoshal, Samson T Jacob.   

Abstract

MicroRNAs (miR) are a class of small ( approximately 21 nucleotide) noncoding RNAs that, in general, negatively regulate gene expression. Some miRs harboring CGIs undergo methylation-mediated silencing, a characteristic of many tumor suppressor genes. To identify such miRs in liver cancer, the miRNA expression profile was analyzed in hepatocellular carcinoma (HCC) cell lines treated with 5-azacytidine (DNA hypomethylating agent) and/or trichostatin A (histone deacetylase inhibitor). The results showed that these epigenetic drugs differentially regulate expression of a few miRs, particularly miR-1-1, in HCC cells. The CGI spanning exon 1 and intron 1 of miR-1-1 was methylated in HCC cell lines and in primary human HCCs but not in matching liver tissues. The miR-1-1 gene was hypomethylated and activated in DNMT1-/- HCT 116 cells but not in DNMT3B null cells, indicating a key role for DNMT1 in its methylation. miR-1 expression was also markedly reduced in primary human hepatocellular carcinomas compared with matching normal liver tissues. Ectopic expression of miR-1 in HCC cells inhibited cell growth and reduced replication potential and clonogenic survival. The expression of FoxP1 and MET harboring three and two miR-1 cognate sites, respectively, in their respective 3'-untranslated regions, was markedly reduced by ectopic miR-1. Up-regulation of several miR-1 targets including FoxP1, MET, and HDAC4 in primary human HCCs and down-regulation of their expression in 5-AzaC-treated HCC cells suggest their role in hepatocarcinogenesis. The inhibition of cell cycle progression and induction of apoptosis after re-expression of miR-1 are some of the mechanisms by which DNA hypomethylating agents suppress hepatocarcinoma cell growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593903      PMCID: PMC2562630          DOI: 10.1158/0008-5472.CAN-07-6655

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.

Authors:  Stephen B Baylin
Journal:  Novartis Found Symp       Date:  2004

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure.

Authors:  Kalpana Ghoshal; Jharna Datta; Sarmila Majumder; Shoumei Bai; Xiaocheng Dong; Mark Parthun; Samson T Jacob
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation.

Authors:  K Ghoshal; S Majumder; Z Li; X Dong; S T Jacob
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

Review 5.  Human FOX gene family (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Oncol       Date:  2004-11       Impact factor: 5.650

6.  Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.

Authors:  Tasneem Motiwala; Kalpana Ghoshal; Anindita Das; Sarmila Majumder; Dieter Weichenhan; Yue-Zhong Wu; Kristen Holman; S Jill James; Samson T Jacob; Christoph Plass
Journal:  Oncogene       Date:  2003-09-25       Impact factor: 9.867

7.  Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression.

Authors:  Kalpana Ghoshal; Sarmila Majumder; Jharna Datta; Tasneem Motiwala; Shoumei Bai; Sudarshana M Sharma; Wendy Frankel; Samson T Jacob
Journal:  J Biol Chem       Date:  2003-11-10       Impact factor: 5.157

8.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.

Authors:  E E Cameron; K E Bachman; S Myöhänen; J G Herman; S B Baylin
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

9.  DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2.

Authors:  Shoumei Bai; Kalpana Ghoshal; Jharna Datta; Sarmila Majumder; Sung Ok Yoon; Samson T Jacob
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

10.  Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.

Authors:  Tasneem Motiwala; Huban Kutay; Kalpana Ghoshal; Shoumei Bai; Hiroyuki Seimiya; Takashi Tsuruo; Saul Suster; Carl Morrison; Samson T Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-08       Impact factor: 11.205

View more
  209 in total

1.  MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer.

Authors:  Akao Zhu; Jiazeng Xia; Junbo Zuo; Shimao Jin; Hong Zhou; Lubin Yao; Hongyu Huang; Zhijun Han
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

3.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms.

Authors:  Y-N Liu; J J Yin; W Abou-Kheir; P G Hynes; O M Casey; L Fang; M Yi; R M Stephens; V Seng; H Sheppard-Tillman; P Martin; K Kelly
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

Review 4.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

5.  HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.

Authors:  Ludivine Renaud; Lillianne G Harris; Santhosh K Mani; Harinath Kasiganesan; James C Chou; Catalin F Baicu; An Van Laer; Adam W Akerman; Robert E Stroud; Jeffrey A Jones; Michael R Zile; Donald R Menick
Journal:  Circ Heart Fail       Date:  2015-09-14       Impact factor: 8.790

6.  Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.

Authors:  Yuanzhi Lu; Satavisha Roy; Gerard Nuovo; Bhuvaneswari Ramaswamy; Tyler Miller; Charles Shapiro; Samson T Jacob; Sarmila Majumder
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

Review 7.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

8.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

9.  Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.

Authors:  Mohd W Nasser; Jharna Datta; Gerard Nuovo; Huban Kutay; Tasneem Motiwala; Sarmila Majumder; Bo Wang; Saul Suster; Samson T Jacob; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

Review 10.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.